List view / Grid view
Pfizer intends to submit biologics license application for bivalent rLP2086…
20 March 2014 | By Pfizer Inc.
Pfizer intends to submit biologics license application for bivalent rLP2086 to U.S. Food and Drug Administration by mid-2014...
Prevenar 13* received European approval...
10 July 2013 | By Pfizer
Prevenar 13* received European approval...
Data from a Phase 3 study of Prevnar 13® met…
12 March 2012 | By Pfizer
Data from a Phase 3 study of Prevnar 13® met all study endpoints...
First pneumococcal conjugate vaccine for adults 50+ has potential to…
30 December 2011 | By Pfizer
First pneumococcal conjugate vaccine for adults 50+ has potential to help address high incidence of pneumococcal pneumonia...
The U.S. FDA issued a 90-day extension to the action…
29 July 2011 | By Pfizer
The U.S. FDA issued a 90-day extension to the action date for the Company’s sBLA for use of Prevnar 13®...
Pfizer Inc. announced that the data from its two pivotal…
9 May 2011 | By Pfizer
Pfizer Inc. announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine...
